CD8A and neoplasm: ETS1 was identified as a key repressor of differentiation from TPEX into TEX, and CRISPR-Cas9 KO of ETS1 in activated CD8+ T cells improve anti-tumour efficacy in a suite of murine melanoma models, alongside increased cytokine production and cytotoxicity (87).